Funding will support the development of Company’s lead product candidate for autoimmune disease as well as novel constructs to treat other indications with significant unmet need.BURLINGAME, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch Capital, among others. The proceeds will support entry of the Company’s lead produ ...